Trial reportBlood cancer journal2018
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B
Trial report in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: Systematic Review and Meta-Analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2021Pooled it
- Effectiveness of antiplatelet therapy for Kawasaki disease: a systematic review.European journal of pediatrics · 2019Pooled it
- Trial
- Stability of the thromboxane BResearch and practice in thrombosis and haemostasis · 2024Article
- Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?Haematologica · 2023Review
- Precision antiplatelet therapy.Research and practice in thrombosis and haemostasis · 2023Article
- Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia.Clinical pharmacology and therapeutics · 2022Article
- Article
- Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment.Research and practice in thrombosis and haemostasis · 2022Article
- Review
- Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera.Current hematologic malignancy reports · 2021Review
- NK Cells in Myeloproliferative Neoplasms (MPN).Cancers · 2021Review
- Lower Antiplatelet Effect of Aspirin in Essential Thrombocythemia than in Coronary Artery Disease.TH open : companion journal to thrombosis and haemostasis · 2021Article
- Platelet Reactivity and Response to Aspirin and Clopidogrel in Patients with Platelet Count Disorders.Cardiology research and practice · 2021Article
- An agenda for future research projects in polycythemia vera and essential thrombocythemia.Haematologica · 2020Article
- From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.Hematology. American Society of Hematology. Education Program · 2019Review
- Role of aspirin in primary prevention of cardiovascular disease.Nature reviews. Cardiology · 2019Review
- Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper.Blood cancer journal · 2019Article
- Measurement of Thromboxane Biosynthesis in Health and Disease.Frontiers in pharmacology · 2019Review
- Thrombotic Prediction Model Based on Epigenetic Regulator Mutations in Essential Thrombocythemia Patients Using Survival Analysis in Recurrent Events.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Once-daily (od), low-dose aspirin (75-100 mg) is recommended to reduce the thrombotic risk of patients with essential thrombocytemia (ET). This practice is based on data extrapolated from other high-risk patients and an aspirin trial in polycythemia vera, with the assumption of similar aspirin pharmacodynamics in the two settings. However, the pharmacodynamics of low-dose aspirin is impaired in ET, reflecting accelerated renewal of platelet cyclooxygenase (COX)-1. ARES is a parallel-arm, placebo-controlled, randomized, dose-finding, phase II trial enrolling 300 ET patients to address two main questions. First, whether twice or three times 100 mg aspirin daily dosing is superior to the standard od regimen in inhibiting platelet thromboxane (TX)A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.